The difference in the size of the cerebral infarctions developed by animals receiving HDAC6 inhibitors or controls evidenced by TTC staining was the most commonly assessed outcome.18,19,24,42,46 Neurological outcomes were less frequently reported, and significant differences in the methods used to assess functional recovery was observed (Tables 1 and 2). This evidence concerns the gene HDAC6 and cerebral infarction.